Syntara (ASX:SNT) reported that it is developing a topical anti-fibrotic drug candidate, SNT-9465, as part of its expanded skin scarring program, according to a Tuesday Australian bourse filing.
The AU$2 million clinical development plan for SNT-9465, funded from existing cash reserves, is designed to demonstrate the drug's safety and tolerability as well as to study its ability to improve both the appearance and physical properties of hypertrophic scars.
A phase 1a dose escalation study in healthy volunteers will be conducted to determine the optimal dose for complete lysyl oxidase inhibition. This will be followed by an open-label phase 1b extension, which will assess improvements in the appearance and composition of hypertrophic scars that are less than 24 months old, after three months of daily treatment.
It expects the results to come in the first half of 2026.
Meanwhile, The Fiona Wood Foundation and the University of Western Australia will conduct an exploratory clinical trial on keloid scarring and Syntara will provide financial and technical support.
The firm's shares rose 3% in recent trading on Tuesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。